Publications by authors named "K Chiswell"
Article Synopsis
- - Atrial fibrillation (AF) is more common in patients with type 2 diabetes and is linked to worse health outcomes; a trial called Harmony Outcomes was conducted to study the effects of albiglutide, a GLP-1 receptor agonist, on cardiovascular events in these patients.
- - The trial included nearly 9,500 participants over 1.6 years and found that those with a history of AF had a higher rate of major adverse cardiac events, but albiglutide treatment reduced these events regardless of AF history.
- - Although both groups on albiglutide experienced fewer AF events than those receiving a placebo, the reduction wasn't statistically significant, indicating that albiglutide can lower cardiovascular risks without
Background: Sociodemographic factors influence outcomes in children with congenital heart disease (CHD). We predict an association between measures of social isolation and outcomes in infants with complex CHD. These measures, racial (RI) and educational (EI) isolation range from 0 to 1, with 0 being no isolation and 1 being fully isolated within a specific population.
View Article and Find Full Text PDFImportance: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) in August 2021 is unknown.
Objective: To examine trends and hospital-level variation in SGLT2i adoption.
Background: An early rhythm control strategy is the preferred management for patients newly diagnosed with atrial fibrillation (AF). A rhythm control strategy, however, has been historically underused for patients from underrepresented racial and ethnic groups (UREGs).
Objective: We aimed to determine whether disparities in rhythm control are present at the initial diagnosis with AF.
Background: Lipoprotein (a) is an independent risk factor for atherosclerotic cardiovascular disease. However, lipoprotein (a) testing remains variable and it is unclear what factors influence testing and if testing changes clinical management.
Methods And Results: A retrospective study using electronic medical record data from 5 health systems identified an atherosclerotic cardiovascular disease cohort divided into those with and without a lipoprotein (a) test between 2019 and 2021.